SUPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Supernus Pharmaceuticals Inc (SUPN) is not a strong buy for a beginner, long-term investor at this moment. While the stock has some positive catalysts such as hedge fund buying and a raised price target by analysts, the technical indicators are neutral to bearish, and the financial performance shows declining net income and EPS. Additionally, insider selling and lack of recent congress trading data or influential figures' activity reduce confidence in this stock as a long-term investment right now.
The MACD is negative and expanding, indicating a bearish trend. The RSI is neutral at 30.494, and moving averages are converging, suggesting indecision in the market. The stock is trading below its pivot level of 50.405, with support at 48.871 and resistance at 51.938.
Hedge funds are increasing their buying activity significantly, with a 146.58% increase over the last quarter. Analysts have raised the price target to $65 from $60 and maintained a Buy rating, citing resolution of supply constraints for Onapgo.
Insiders are selling heavily, with a 2510.70% increase in selling activity over the last month. The financials show a significant drop in net income (-126.78% YoY) and EPS (-125.93% YoY). No recent news or congress trading data is available to support the stock.
In Q4 2025, revenue increased by 21.48% YoY to $211.57M. However, net income dropped to -$4.11M (-126.78% YoY), and EPS fell to -$0.07 (-125.93% YoY). Gross margin decreased slightly to 78.43% (-1.53% YoY).
TD Cowen raised the price target to $65 from $60 and maintained a Buy rating, citing resolution of supply constraints and improved production capacity.
